Delivery Order SPE2DB22D1202-SPE2DB25FVMG2
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,814.83 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. The contract is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The award was executed on June 2, 2025, with an ultimate completion date of June 3, 2025, and performance...
- The Defense Logistics Agency (DLA) awarded a $1,896.96 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This firm fixed-price delivery order was competitively awarded with no set-aside designation and carries an ultimate completion date of July 23, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,609.51 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml Suspension (180 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price delivery order was issued on August 14, 2025, with an ultimate completion date of August 15, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The...
- The Defense Logistics Agency awarded a $1,085.70 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml), a medication commonly used to treat attention deficit hyperactivity disorder. This firm fixed-price delivery order, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, was competitively awarded with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $1,517.14 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml), a medication used to treat attention-deficit/hyperactivity disorder. This firm fixed price contract, awarded on June 5, 2025, with an ultimate completion date of June 6, 2025, represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The award utilized no set-aside...
- The Defense Logistics Agency awarded a $3,274.31 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), a pharmaceutical product used in treating attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension (120 mL), a medication used to treat attention-deficit/hyperactivity disorder. This firm fixed-price delivery order, valued at $2,962.82, represents a non-competitive set-aside award and is scheduled for completion by September 23, 2025. The product will be delivered to the vendor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,308.96 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This competitively awarded, firm fixed price delivery order was issued on September 2, 2025, with an ultimate completion date of September 3, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,202.16 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL), a medication used to treat attention deficit hyperactivity disorder. The award was made on July 21, 2025, with a completion date of July 22, 2025, under a firm fixed-price delivery order contract with no set-aside designation. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) at a ceiling value of $1,118.30. This delivery order represents a firm fixed-price procurement with no set-aside designation, issued under a competitive process. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVMG2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,302.14 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml), a medication used to treat attention deficit hyperactivity disorder. The contract is a firm fixed price delivery order with no set-aside designation, reflecting AmerisourceBergen's qualification to compete in open federal procurement. The award was issued on September 24, 2025, with an ultimate completion date of September 25, 2025, and performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive prime vendor contract enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, including support to the Defense Health Agency and U.S. Coast Guard. The company's federal contract portfolio demonstrates consistent capability in fulfilling medical supply requirements across multiple therapeutic domains through competitively awarded contracts with firm fixed pricing.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 9/24/25 |